Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Mohamedali, Khalid A ^a   Ran, Sophia ^b   Gomez Manzano, Candelaria ^a   Ramdas, Latha ^a   Xu, Jing ^a,e   Kim, Sehoon ^a,f   Cheung, Lawrence H ^a   Hittelman, Walter N ^a   Zhang, Wei ^a   Waltenberger, Johannes ^c   Thorpe, Philip E ^d   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN 121 GELONIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; GEL PROTEIN, GELONIUM MULTIFLORUM; RIBOSOME INACTIVATING PROTEIN 1; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ADHESION; CHEMOTAXIS; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DNA FINGERPRINTING; DRUG BINDING; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG UPTAKE; EX VIVO STUDY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM; VASCULARIZATION; ANIMAL; AORTA; CHICK EMBRYO; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENDOTHELIUM CELL; GENETICS; METABOLISM; SWINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; CHICK EMBRYO; CHICKENS; CHORIOALLANTOIC MEMBRANE; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80051661162     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-358     Document Type: Article

References (38)

1. Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res 2009, 335:241-248. 10.1007/s00441-008-0646-0, 2788502, 18752004.
2. Bernatchez PN, Rollin S, Soker S, Sirois MG. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. J Cell Biochem 2002, 85:629-639. 10.1002/jcb.10155, 11968003.
3. Han YS, Lee JE, Jung JW, Lee JS. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009, 247:541-548. 10.1007/s00417-008-0976-3, 18953554.
4. Karamysheva AF. Mechanisms of angiogenesis. Biochemistry (Mosc) 2008, 73:751-762.
5. Pourgholami MH, Morris DL. Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc Hematol Agents Med Chem 2008, 6:343-347. 10.2174/187152508785909528, 18855647.
6. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 2001, 276:26969-26979. 10.1074/jbc.M103213200, 11350975.
7. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009, 335:261-269. 10.1007/s00441-008-0675-8, 18766380.
8. Dvorak HF. VPF/VEGF and the angiogenic response. Semin Perinatol 2000, 24:75-78. 10.1016/S0146-0005(00)80061-0, 10709865.
9. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 2005, 7:912-920. 10.1593/neo.05292, 1550288, 16242074.
10. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 2002, 99:7866-7871. 10.1073/pnas.122157899, 122986, 12060733.
11. Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia 2005, 7:486-496. 10.1593/neo.04631, 1501168, 15967101.
12. Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res 2006, 66:10919-10928. 10.1158/0008-5472.CAN-06-0459, 17108129.
13. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone N. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res 2011,
14. Akiyama H, Mohamedali KA, RL ES, Kachi S, Shen J, Hatara C, Umeda N, Hackett SF, Aslam S, Krause M, Lai H, Rosenblum MG, Campochiaro PA. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. Mol Pharmacol 2005, 68:1543-1550.
15. Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, Vogel H, Hou LC, Tse V, Rosenblum MG, Chen X. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 2007, 48:445-454.
16. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996, 271:7788-7795. 10.1074/jbc.271.13.7788, 8631822.
17. Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, de Vos A, Gerritsen ME. Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol 2002, 22:1797-1803. 10.1161/01.ATV.0000038995.31179.24, 12426207.
18. Kroll J, Waltenberger J. A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun 1999, 265:636-639. 10.1006/bbrc.1999.1729, 10600473.
19. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269:26988-26995.
20. Kanellopoulos J, Rossi G, Metzger H. Preparative isolation of the cell receptor for immunoglobulin E. J Biol Chem 1979, 254:7691-7697.
21. Ran S, Huang X, Downes A, Thorpe PE. Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy. Neoplasia 2003, 5:297-307. 1502417, 14511401.
22. Brooks PC, Montgomery AM, Cheresh DA. Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol 1999, 129:257-269.
23. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000, 97:1749-1753. 10.1073/pnas.040560897, 26507, 10677529.
24. Verhoef C, de Wilt JH, Verheul HM. Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Curr Pharm Des 2006, 12:2623-2630. 10.2174/138161206777698756, 16842162.
25. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295. 154450, 12727920.
26. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004, 40:1292-1301. 10.1016/j.ejca.2004.02.014, 15177487.
27. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004, 38:1258-1264. 10.1345/aph.1D470, 15187215.
28. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398. 10.1073/pnas.172398299, 123267, 12177445.
29. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008, 26:399-405. 10.1200/JCO.2007.11.9230, 18202416.
30. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008, 7:3670-3684. 10.1158/1535-7163.MCT-08-0715, 2637411, 19074844.
31. Aoki M, Kanamori M, Yudoh K, Ohmori K, Yasuda T, Kimura T. Effects of vascular endothelial growth factor and E-selectin on angiogenesis in the murine metastatic RCT sarcoma. Tumour Biol 2001, 22:239-246. 10.1159/000050622, 11399949.
32. Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y, Cherrington J, McMahon G, Shibuya M, Kuwano M, Ono M. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther 2002, 1:295-302.
33. Fakhari M, Pullirsch D, Paya K, Abraham D, Hofbauer R, Aharinejad S. Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J Pediatr Surg 2002, 37:582-587. 10.1053/jpsu.2002.31614, 11912515.
34. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001, 106:148-156. 10.1159/000046610, 11815711.
35. Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H, Louvrou A. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 2002, 33:863-870. 10.1053/hupa.2002.126879, 12378509.
36. Verheul HM, Pinedo HM. The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor Angiogenesis and Early Clinical Development of VEGF-Receptor Kinase Inhibitors. Clin Breast Cancer 2000, 1(Suppl 1):S80-S84.
37. Rosenblum MG, Cheung LH, Liu Y, Marks JW. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003, 63:3995-4002.
38. Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 2007, 6:460-470. 10.1158/1535-7163.MCT-06-0254, 17267661.